A Caltech Library Service

Antitumor Activity of β-Cyclodextrin Polymer−Camptothecin Conjugates

Cheng, Jianjun and Khin, Kay T. and Davis, Mark E. (2004) Antitumor Activity of β-Cyclodextrin Polymer−Camptothecin Conjugates. Molecular Pharmaceutics, 1 (3). pp. 183-193. ISSN 1543-8384. doi:10.1021/mp049966y.

Full text is not posted in this repository. Consult Related URLs below.

Use this Persistent URL to link to this item:


Antitumor activity of linear, β-cyclodextrin polymer (CDP)−camptothecin (CPT) conjugates (HGGG6, LGGG10, HG6, and HGGG10) is investigated in nude mice bearing human LS174T colon carcinoma tumors. These conjugates differ in polymer molecular mass [97 kDa (H) or 35 kDa (L)], CDP−CPT linker structure [glycine (G) or triglycine (GGG)], and CPT loading [ca. 6 wt % (6) or 10 wt % (10)]. Maximum tolerable doses (MTDs) of the three conjugates, LGGG10, HG6, and HGGG10, are determined to be 36, 9, and 9 mg of CPT/kg, respectively, while the MTD of the CDP alone exceeds 240 mg/kg (highest value investigated). The three CDP−CPT conjugates with high polymer molecular masses (HGGG6, HG6, and HGGG10) demonstrate antitumor activity at their MTDs superior to that of CPT at the same amount and to that of irinotecan at its optimal dose. They also show tumor growth inhibition that is superior to that of the conjugate containing the low-molecular mass polymer (LGGG10) at the same dose of CPT. No significant effects of CPT weight loading or linker structure on tumor growth delay are observed. However, conjugates containing G appear to be less toxic than these with GGG. These antitumor studies demonstrate that the CDP-based conjugates of CPT exhibit tumor growth inhibition superior to that of CPT or irinotecan at the conditions employed in this study. The striking observation is that a short course of treatment with the polymer conjugates gives long-term control of tumor growth that does not occur with either CPT or irinotecan. Intracellular CDPs are demonstrated by analyzing cells that were cultured in the presence of rhodamine-labeled CDP (HRhod) containing medium using both confocal microscopy and flow cytometry. The long-term therapeutic efficacy of CDP−CPT conjugates observed in mice may in part be due to the sustained release of CPT from these conjugates in the acidic, intracellular compartments since these conjugates are shown to have significantly slower release rates at acidic pH than at physiological pH.

Item Type:Article
Related URLs:
URLURL TypeDescription
Davis, Mark E.0000-0001-8294-1477
Additional Information:© 2004 American Chemical Society. Received 23 February 2004. Published online 3 April 2004. Published in print 1 May 2004. We thank Dr. Shih-Fong Chen, Anna Avrutskaya, Walter Kruger, Beth Hollister, and Alan Meshaw at the Piedmont Research Center; our colleagues Drs. Nathalie Bellocq, Leonard Borrmann, Christopher Dartt, John Guastella, and Suzie Hwang Pun and Mr. Gregory Jensen at Insert Therapeutics for their helpful discussions; and Dr. Randall Johnson for his critical suggestions and comments throughout this study. We especially thank Swaroop Mishra (California Institute of Technology) for his help with the confocal microscopy.
Subject Keywords:Camptothecin; cyclodextrin-based polymer; polymer-drug conjugates; antitumor activity; sustained release; drug delivery
Issue or Number:3
Record Number:CaltechAUTHORS:20170728-145956263
Persistent URL:
Official Citation:Antitumor Activity of β-Cyclodextrin Polymer−Camptothecin Conjugates Jianjun Cheng, Kay T. Khin, and Mark E. Davis Molecular Pharmaceutics 2004 1 (3), 183-193 DOI: 10.1021/mp049966y
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:79557
Deposited By: Ruth Sustaita
Deposited On:28 Jul 2017 23:00
Last Modified:15 Nov 2021 17:48

Repository Staff Only: item control page